Evaluation of DNA methylation in BDNF, SLC6A4, NR3C1 and FKBP5 before and after treatment with selective serotonin-reuptake inhibitor in major depressive disorder
| Autor: | Saeid Mohammadi, Abbas Beh-Pajooh, Mahnaz Ahmadimanesh, Mohsen Amini, Mahmoud Ghazi-Khansari, Seyed Adel Moallem, Rohollah Hosseini, Yazdan Hasani Nourian, Mohammad Hossein Ghahremani |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Epigenomics. 14:1269-1280 |
| ISSN: | 1750-192X 1750-1911 |
| Popis: | Aim: To identify the DNA methylation status of related genes in major depressive disorder following selective serotonin-reuptake inhibitor treatment. Materials & methods: 45 patients with major depressive disorder and 45 healthy volunteers were considered experimental and control groups, respectively. High-resolution melting real-time PCR was implemented to evaluate DNA methylation. Results: After 100 days of selective serotonin-reuptake inhibitor treatment, methylation of promoter CpG sites of BDNF, NR3C1, FKBP5 and SLC6A4 was significantly reduced. Compared with before treatment, patients' Hamilton Depression Rating Scale scores were significantly reduced after selective serotonin-reuptake inhibitor treatment (p ≤ 0.0001). Conclusion: Based on the proven effect of antidepressants on DNA methylation and gene expression, these medications can improve the treatment process and reduce depression scores after treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|